Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
valaciclovir
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Valaciclovir is an oral antiviral medication used to treat infections caused by herpes viruses, including herpes simplex virus (HSV) types 1 and 2 (causing oral and genital herpes), varicella-zoster virus (VZV; causing shingles and chickenpox), and for the prevention of cytomegalovirus in high-risk transplant patients. It is a prodrug that is rapidly converted in the body to acyclovir, its active metabolite. Acyclovir acts as a nucleoside analog DNA polymerase inhibitor. Its mechanism involves competitive inhibition of viral DNA polymerase, incorporation into viral DNA leading to chain termination, and inactivation of the viral DNA polymerase enzyme. Valaciclovir does not cure herpes infections but reduces symptoms, frequency of outbreaks, pain, itching, healing time for sores, and risk of transmission[1][4][5][6].
- Brand names
- Valtrex
- Other names
- acyclovir L-valyl esterL-valyl ester of acyclovir
02
Targets
HSV-TK (Herpes simplex virus type 1 thymidine kinase (HSV1-TK))HSV DNA pol (Herpes simplex virus DNA polymerase)
Beyond the preview
Go deeper on valaciclovir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on valaciclovir.